EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery

Avery Brown, Suhani S Patel, Akio Kozato iD, Babak J Orandi, Allan Massie, Alexander Hien Vu, Eduardo Somoza, Tony Mei, Sunita Desai, Donglan S Zhang, Dorry Segev, Akuezunkpa Ude Welcome und 3 weitere

Obesity · 2026-08 · 34 (8) · 1583-1591

DOI: 10.1002/oby.70246 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Obesity, online erschienen am 25.06.2026. Verfasst von Avery Brown und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA. Hauptthemen laut MEDLINE: Tirzepatide, Glucagon-Like Peptides, Bariatric Surgery, Obesity, Morbid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Directly compare the real‐world effectiveness of semaglutide and tirzepatide to bariatric operations: sleeve gastrectomy and gastric bypass.

Methods

This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP‐1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024. Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models. Intention‐to‐treat (any GLP‐1RA) and per‐protocol (1 year of continuous GLP‐1RA orders) analyses were performed.

Results

Of 44,025 patients studied, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years post treatment: semaglutide ( n = 25,804) TWL (95% CI): 5.4% (5.3%–5.6%), 6.5% (6.4%–6.7%), and 7.4% (7.3%–7.6%); tirzepatide ( n = 7308): 9.1% (8.9%–9.4%) and 10.8% (10.2%–11.3%); sleeve gastrectomy ( n = 8728): 24.4% (24.3%–24.6%), 22.4% (22.3%–22.5%), and 22.0% (21.8%–22.1%); gastric bypass ( n = 2185): 29.8% (29.7%–29.9%), 28.1% (28.0%–28.2%), and 28.4% (28.3%–28.5%). With 1 year of continuous GLP‐1RA, findings were: semaglutide TWL: 7.2% (7.0%–7.4%), 8.0% (7.8%–8.2%), and 8.8% (8.6%–9.0%); tirzepatide TWL: 11.7% (11.4%–11.9%) and 11.9% (11.5%–12.3%).

Conclusions

In this retrospective two‐center study, bariatric surgery was associated with greater weight loss than GLP‐1RAs among patients eligible for both options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideGlucagon-Like PeptidesBariatric SurgeryObesity, MorbidHumansSemaglutideFemaleWeight LossMiddle AgedAdultMaleTreatment OutcomeGastric Bypass

Substanzen

SemaglutideTirzepatideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA.
  • Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
  • Center for Surgical and Transplant Applied Research, NYU Langone Health, New York, New York, USA.
  • Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Surgery, NYU Langone Hospital-Brooklyn, Brooklyn, New York, USA.

ORCID-Profile: Akio Kozato, Karan R Chhabra

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Brown, A., Patel, S. S., Kozato, A., Orandi, B. J., Massie, A., Vu, A. H., Somoza, E., Mei, T., Desai, S., Zhang, D. S., Segev, D., Welcome, A. U., Ren-Fielding, C., Parikh, M., & Chhabra, K. R. (2026). Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity, 34(8), 1583-1591. https://doi.org/10.1002/oby.70246

Vancouver

Brown A, Patel SS, Kozato A, Orandi BJ, Massie A, Vu AH, et al. Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity. 2026;34(8):1583-1591. doi:10.1002/oby.70246

BibTeX
@article{Brown2026,
  author = {Brown, Avery and Patel, Suhani S and Kozato, Akio and Orandi, Babak J and Massie, Allan and Vu, Alexander Hien and Somoza, Eduardo and Mei, Tony and Desai, Sunita and Zhang, Donglan S and Segev, Dorry and Welcome, Akuezunkpa Ude and Ren-Fielding, Christine and Parikh, Manish and Chhabra, Karan R},
  title = {Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {8},
  pages = {1583--1591},
  doi = {10.1002/oby.70246}
}
Kostenlos starten →